Research programme: AMP-activated protein kinase stimulants - Energenesis Biomedical

Drug Profile

Research programme: AMP-activated protein kinase stimulants - Energenesis Biomedical

Alternative Names: ENERGI F704; ENERGI F705; ENERGI F706; ENERGI F707; ENERGI-F703

Latest Information Update: 06 May 2016

Price : $50

At a glance

  • Originator Energenesis Biomedical
  • Class
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation; Metabolic disorders; Neurodegenerative disorders; Wounds

Most Recent Events

  • 06 May 2016 Preclinical trials in Cancer in Taiwan (unspecified route) before May 2016
  • 06 May 2016 Preclinical trials in Neurodegenerative disorders in Taiwan (unspecified route) before May 2016
  • 06 May 2016 Preclinical trials in Metabolic disorders in Taiwan (unspecified route) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top